• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Evolus Inc.

    11/13/24 5:38:05 PM ET
    $EOLS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $EOLS alert in real time by email
    SC 13G/A 1 eols13ga2.htm

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934
    (Amendment No. 2)*

     

     

    Evolus, Inc.

    (Name of Issuer)

     

     

    Common Stock, par value $0.00001 per share

    (Title of Class of Securities)

     

     

    30052C107

    (CUSIP Number)

     

     

    September 30, 2024

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    [X]       Rule 13d-1(b)

     

    [X]       Rule 13d-1(c)

     

    [ ]       Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

     

     1 
    CUSIP No. 30052C107

     

    1.Names of Reporting Persons.

    Stonepine Capital Management, LLC

     

    2.Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ______

    (b) X

     

    3. SEC Use Only

     

    4.Citizenship or Place of Organization Delaware

     

    Number of

    Shares

    Beneficially

    Owned by

    Each Reporting

    Person With:

    5. Sole Voting Power 0

     

    6. Shared Voting Power 1,369,821

     

    7. Sole Dispositive Power 0
    8. Shared Dispositive Power 1,369,821

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 1,369,821

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See
    Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 2.2%

     

    12.Type of Reporting Person (See Instructions) IA, OO

     

     2 
    CUSIP No. 30052C107

     

    1.Names of Reporting Persons.

    Stonepine Capital, L.P.

     

    2.Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ______

    (b) X

     

    3. SEC Use Only

     

    4.Citizenship or Place of Organization Delaware

     

    Number of

    Shares

    Beneficially

    Owned by

    Each Reporting

    Person With:

    5. Sole Voting Power 0

     

    6. Shared Voting Power 1,369,821

     

    7. Sole Dispositive Power 0
    8. Shared Dispositive Power 1,369,821

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 1,369,821

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See
    Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 2.2%

     

    12.Type of Reporting Person (See Instructions) PN

     

     3 
    CUSIP No. 30052C107
    1.Names of Reporting Persons.

    Stonepine GP, LLC

     

    2.Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ______

    (b) X

     

    3. SEC Use Only

     

    4.Citizenship or Place of Organization Delaware

     

    Number of

    Shares

    Beneficially

    Owned by

    Each Reporting

    Person With:

    5. Sole Voting Power 0

     

    6. Shared Voting Power 1,369,821

     

    7. Sole Dispositive Power 0
    8. Shared Dispositive Power 1,369,821

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 1,369,821

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See
    Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 2.2%

     

    12.Type of Reporting Person (See Instructions) OO

     

     4 
    CUSIP No. 30052C107

     

    1.Names of Reporting Persons.

    Jon M. Plexico

     

    2.Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ______

    (b) X

     

    3. SEC Use Only

     

    4.Citizenship or Place of Organization U.S.A.

     

    Number of

    Shares

    Beneficially

    Owned by

    Each Reporting

    Person With:

    5. Sole Voting Power 0

     

    6. Shared Voting Power 1,369,821

     

    7. Sole Dispositive Power 0
    8. Shared Dispositive Power 1,369,821

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 1,369,821

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See
    Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 2.2%

     

    12.Type of Reporting Person (See Instructions) HC, IN

     

     5 
    CUSIP No. 30052C107

     

    Item 1.

     

    (a)Name of Issuer

    Evolus, Inc.

     

    (b)Address of Issuer’s Principal Executive Offices

    520 Newport Center Drive Suite 1200, Newport Beach, CA 92660

     

     

    Item 2.

     

    (a)The names of the persons filing this statement are:


    Stonepine Capital Management, LLC, a Delaware limited liability company (“Stonepine”)

     

    Stonepine Capital, L.P., a Delaware limited partnership (the “Partnership”)

     

    Stonepine GP, LLC, a Delaware limited liability company (the “General Partner”)

     

    Jon M. Plexico (collectively, the “Filers”)

     

    Stonepine and the General Partner are the investment adviser and general partner, respectively, of the Partnership. Mr. Plexico is the control person of Stonepine and the General Partner. The Filers are filing this Schedule 13G jointly, but not as members of a group, and each disclaims membership in a group. Each Filer also disclaims beneficial ownership of the Stock except to the extent of that person’s pecuniary interest therein. In addition, the filing of this Schedule 13G on behalf of the Partnership should not be construed as an admission that it is, and it disclaims that it is, a beneficial owner, as defined in Rule 13d-3 under the Act, of any of the Stock covered by this Schedule 13G.

     

    (b)The principal business office of the Filers is located at

     

    919 NW Bond Street, Suite 204

    Bend, OR 97703

     

    (c)For citizenship of Filers, see Item 4 of the cover sheet for each Filer.

     

    (d)This statement relates to the Issuer’s Common Stock, par value $0.00001 per share (the “Stock”).

     

    (e)The CUSIP number of the Issuer is: 30052C107
     6 
    CUSIP No. 30052C107
    Item 3.If this statement is filed pursuant to rule 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a)[ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

     

    (b)[ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

     

    (c)[ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

     

    (d)[ ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

     

    (e)[X] An investment adviser in accordance with section 240.13d-1(b)(1)(ii)(E). As to Stonepine and the General Partner.

     

    (f)[ ] An employee benefit plan or endowment fund in accordance with section 240.13d-1(b)(1)(ii)(F).

     

    (g)[X] A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G). As to Mr. Plexico.

     

    (h)[ ] A savings association as defined in section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).

     

    (i)[ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3).

     

    (j)[ ] A non-U.S. institution in accordance with §240.13d-1(b)(ii)(J).

     

    (k)[ ] Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution _______________________________________________________________.

     

    Item 4.Ownership.

     

    See Items 5-9 and 11 of the cover page for each Filer.

     

    The percentages reported in this Schedule 13G are based on 63,094,482 shares of Common Stock outstanding as of July 26, 2024, as reported in the Form 10-Q filed by the Issuer on July 31, 2024.

     

    Item 5.Ownership of Five Percent or Less of a Class

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ X ].

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    The Partnership holds the Stock for the benefit of its investors and has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Stock.

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

     

    Not applicable.

     

    Item 8.Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9.Notice of Dissolution of Group

     

    Not applicable.


    Item 10.
    Material to Be Filed as Exhibits

    Agreement Regarding Joint Filing of Statement on Schedule 13D or 13G.

    Item 11.Certification of Stonepine, the General Partner and Mr. Plexico

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

    Certification of the Partnership

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     7 
    CUSIP No. 30052C107

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: November 13, 2024

     

     

    STONEPINE CAPITAL MANAGEMENT, LLC


    By: /s/ Jon M. Plexico
    Jon M. Plexico
    Managing Member

     

     
     

    STONEPINE CAPITAL, L.P.

    By: Stonepine GP, LLC,
    General Partner

    By: /s/ Jon M. Plexico
    Jon M. Plexico
    Managing Member

     

     
     

    STONEPINE GP, LLC


    By: /s/ Jon M. Plexico
    Jon M. Plexico
    Managing Member

     

     
     

     

    /s/ Jon M. Plexico

    Jon M. Plexico

     
     8 
    CUSIP No. 30052C107

    EXHIBIT A

     

    AGREEMENT REGARDING JOINT FILING

    OF STATEMENT ON SCHEDULE 13D OR 13G

     

    The undersigned agree to file jointly with the Securities and Exchange Commission (the “SEC”) any and all statements on Schedule 13D or Schedule 13G or Forms 3, 4 or 5(and any amendments or supplements thereto) required under section 13(d) and 16(a) of the Securities Exchange Act of 1934, as amended, in connection with purchases by the undersigned of the securities of any issuer. For that purpose, the undersigned hereby constitute and appoint Stonepine Capital Management, LLC, a Delaware limited liability company, as their true and lawful agent and attorney-in-fact, with full power and authority for and on behalf of the undersigned to prepare or cause to be prepared, sign, file with the SEC and furnish to any other person all certificates, instruments, agreements and documents necessary to comply with section 13(d) and section 16(a) of the Securities Exchange Act of 1934, as amended, in connection with said purchases, and to do and perform every act necessary and proper to be done incident to the exercise of the foregoing power, as fully as the undersigned might or could do if personally present.

     

    Dated: October 10, 2024

     

     

    STONEPINE CAPITAL MANAGEMENT, LLC


    By: /s/ Jon M. Plexico
    Jon M. Plexico
    Managing Member

     

     

    STONEPINE CAPITAL, L.P.

    By: Stonepine GP, LLC,
    General Partner

    By: /s/ Jon M. Plexico
    Jon M. Plexico
    Managing Member

     

     

    STONEPINE GP, LLC


    By: /s/ Jon M. Plexico
    Jon M. Plexico
    Managing Member

     

     

     

    /s/ Jon M. Plexico

    Jon M. Plexico

     

     

     

     

    Get the next $EOLS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $EOLS

    DatePrice TargetRatingAnalyst
    8/6/2025Buy → Hold
    Needham
    4/17/2025$21.00Buy
    BTIG Research
    1/29/2024$10.00 → $16.00Equal Weight → Overweight
    Barclays
    6/23/2022$18.00Buy
    Needham
    5/12/2022$8.00 → $10.00Underweight → Equal Weight
    Barclays
    1/20/2022$11.00Hold → Buy
    Truist
    11/3/2021$22.00 → $15.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $EOLS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Moatazedi David

    4 - Evolus, Inc. (0001570562) (Issuer)

    3/20/26 7:19:00 PM ET
    $EOLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Avelar Rui

    4 - Evolus, Inc. (0001570562) (Issuer)

    3/20/26 7:19:06 PM ET
    $EOLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Avelar Rui

    4 - Evolus, Inc. (0001570562) (Issuer)

    3/18/26 8:00:32 PM ET
    $EOLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EOLS
    SEC Filings

    View All

    SEC Form 10-Q filed by Evolus Inc.

    10-Q - Evolus, Inc. (0001570562) (Filer)

    5/4/26 5:00:45 PM ET
    $EOLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Evolus Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Evolus, Inc. (0001570562) (Filer)

    5/4/26 4:05:48 PM ET
    $EOLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEF 14A filed by Evolus Inc.

    DEF 14A - Evolus, Inc. (0001570562) (Filer)

    4/29/26 9:28:20 AM ET
    $EOLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EOLS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Regenerative Medicine's Newest Public Company Is Building Tissue, Not Replacing It

    Issued on behalf of Conexeu Sciences Inc.Companies mentioned: Conexeu Sciences Inc. (NASDAQ:CNXU), Integra LifeSciences Holdings Corporation (NASDAQ:IART), Evolus, Inc. (NASDAQ:EOLS), Bioventus Inc. (NASDAQ:BVS), Mesoblast Limited (NASDAQ:MESO)KEY TAKEAWAYSA fresh Nasdaq debut. Conexeu Sciences Inc. (NASDAQ:CNXU) began trading on May 21, 2026, marking the public-market entry of a Reno-based regenerative tissue platform company targeting wound care, breast reconstruction, and aesthetic medicine — three of the largest unmet-need categories in healthcare today.One platform, multiple markets. Conexeu's proprietary CXU™ extracellular matrix platform is designed to scale across multiple addressabl

    5/22/26 10:31:00 AM ET
    $BVS
    $EOLS
    $IART
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Biotechnology: Biological Products (No Diagnostic Substances)

    Evolus to Participate in The Jefferies Global Healthcare Conference

    Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced members of its management team will participate in a fireside chat and investor meetings at the upcoming Jefferies Global Healthcare Conference in New York City. The fireside chat will take place on Thursday, June 4th, 2026, at 12:50 PM ET. The fireside chat can be accessed on the Investor Relations page of the Evolus website here. A replay of the webcast will be available 90 days after the date of the presentation. About Evolus, Inc. Evolus (NASDAQ:EOLS) is a global performance beauty company redefining the aesthetic injectable market for the

    5/19/26 8:30:00 AM ET
    $EOLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Evolus Announces Commercial Launch of Estyme® Injectable Hyaluronic Acid Gels in Europe

    Evolus, Inc. (NASDAQ:EOLS), a global performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that the commercial launch of Estyme® (pronounced "esteem"), its injectable hyaluronic acid (HA) gel collection in Europe, is scheduled for May 16th, marking the company's entry into the international dermal filler market. The Estyme® collection includes four injectable HA gels that will cover a wide range of applications. The collection includes Estyme® Smooth and Estyme® Form, which are currently marketed in the United States under the brand Evolysse®, along with the debut of two products including Estyme® Lips and the flagship product in th

    5/11/26 8:30:00 AM ET
    $EOLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EOLS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Evolus downgraded by Needham

    Needham downgraded Evolus from Buy to Hold

    8/6/25 7:20:38 AM ET
    $EOLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BTIG Research initiated coverage on Evolus with a new price target

    BTIG Research initiated coverage of Evolus with a rating of Buy and set a new price target of $21.00

    4/17/25 8:32:06 AM ET
    $EOLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Evolus upgraded by Barclays with a new price target

    Barclays upgraded Evolus from Equal Weight to Overweight and set a new price target of $16.00 from $10.00 previously

    1/29/24 7:09:38 AM ET
    $EOLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EOLS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Stewart Brady bought $204,486 worth of shares (30,000 units at $6.82), increasing direct ownership by 51% to 88,629 units (SEC Form 4)

    4 - Evolus, Inc. (0001570562) (Issuer)

    8/18/25 4:28:22 PM ET
    $EOLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director White Albert G Iii bought $189,000 worth of shares (20,000 units at $9.45), increasing direct ownership by 66% to 50,378 units (SEC Form 4)

    4 - Evolus, Inc. (0001570562) (Issuer)

    6/10/25 5:04:47 PM ET
    $EOLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EOLS
    Leadership Updates

    Live Leadership Updates

    View All

    Telix Appoints David Gill as Non-Executive Director

    MELBOURNE, Australia and INDIANAPOLIS, April 02, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, "Telix") today announces the appointment of David Gill as a Non-Executive Director (NED), as part of Board expansion and succession planning. The appointment is effective May 11, 20261. Mr. Gill is expected to be appointed as Chair in due course, succeeding Dr. Mark Nelson who will remain on the Board as a NED. Mr. Gill is a life sciences executive with over 35 years' experience in senior general management and financial leadership roles across commercial and clinical-stage biopharmaceutical (including radiopharmaceuticals) and medical device companies. He current

    4/1/26 7:53:07 PM ET
    $EOLS
    $TLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Evolus Announces the Appointment of Tatjana Mitchell as Chief Financial Officer

    Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced the appointment of Tatjana Mitchell as its Chief Financial Officer, effective September 8, 2025. Ms. Mitchell has over 20 years of strategic and operational finance leadership across both public and private companies in retail, consumer, data, and technology-driven businesses. She brings a proven track record of driving revenue growth, scaling organizations, and leading transformation efforts through disciplined financial management and strategic execution. Most recently, Ms. Mitchell served as Senior Vice President of Corporate Finance at Experian

    9/8/25 8:30:00 AM ET
    $EOLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Evolus Announces Appointment of Albert G. White III to Board of Directors

    Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced the appointment of Albert G. White III, President and Chief Executive Officer of The Cooper Companies, Inc. to the Evolus Board of Directors, effective July 1. Mr. White will also serve as a member of Evolus' Compensation Committee. "We are pleased to welcome Al White to the Evolus Board," said Vik Malik, Chairman of the Board of Directors. "Al's extensive leadership experience, industry knowledge, and proven track record of building a leading medical technology company will be a valuable resource as Evolus embarks on a path from a single-product aes

    7/1/24 8:00:00 AM ET
    $COO
    $EOLS
    Ophthalmic Goods
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $EOLS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Evolus Inc.

    SC 13G/A - Evolus, Inc. (0001570562) (Subject)

    11/14/24 4:50:28 PM ET
    $EOLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Evolus Inc.

    SC 13G/A - Evolus, Inc. (0001570562) (Subject)

    11/14/24 4:00:06 PM ET
    $EOLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Evolus Inc.

    SC 13G/A - Evolus, Inc. (0001570562) (Subject)

    11/13/24 5:38:05 PM ET
    $EOLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EOLS
    Financials

    Live finance-specific insights

    View All

    Evolus Reports First Quarter 2026 Financial Results; Company Delivers Second Consecutive Quarter of Positive Adjusted EBITDA and Reaffirms Full-Year Outlook

    Global Net Revenue of $73.1 Million for the First Quarter of 2026, Up 7% Over the Prior Year and Against the Highest Growth Quarter of 2025 GAAP Operating Loss of $6.8 Million and Adjusted EBITDA of $0.6 Million for the First Quarter of 2026, Representing the Second Consecutive Quarter of Positive Adjusted EBITDA and a Significant Improvement from a Loss of $5.5 Million in the Prior Year Period Reaffirms Full-Year 2026 Net Revenue Guidance of $327 Million to $337 Million and Non-GAAP Operating Expenses of $210 Million to $216 Million; Company Continues to Expect to Achieve a Low- to Mid-Single Digit Adjusted EBITDA Margin in 2026 Evolus, Inc. (NASDAQ:EOLS), a global performance be

    5/4/26 4:05:00 PM ET
    $EOLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Evolus to Report First Quarter Financial Results on May 4, 2026

    Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its first quarter 2026 financial results on Monday, May 4, 2026, after the U.S. financial markets close. Evolus management will host a conference call and live webcast to discuss these results at 4:30 p.m. ET that same day. A question-and-answer session will follow management's remarks. To participate in the conference call, dial (877) 407-6184 (U.S.) or (201) 389-0877 (international) or connect live via webcast on the Investor Relations page of the Evolus website here. Following the completion of the call, a telephonic replay

    4/14/26 8:30:00 AM ET
    $EOLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Evolus Reports Fourth Quarter and Full-Year 2025 Financial Results; Delivers Sixth Consecutive Year of Double-Digit Growth and Expects Sustainable Profitability1 Beginning in 2026

    Total Net Revenue of $90.3 Million for the Fourth Quarter and $297.2 Million for the Full-Year 2025, Representing Growth of 14% and 12% Over the Prior Year Delivered GAAP Operating Income of $4.2 Million for the Fourth Quarter; Non-GAAP Operating Income of $7.1 Million for Q4 2025, Above Prior Guidance Range Full-Year GAAP Operating Expenses of $229.8 Million in 2025; Non-GAAP Operating Expense of $209.7 Million, Within the Company's Guidance Range of $208 Million to $213 Million, with Second Half 2025 Expenses Declining 4% Compared to the First Half, Driving Meaningful Year-Over-Year Operating Leverage in the Second Half 2026 Net Revenue Guidance of $327 Million to $337 Million,

    3/3/26 4:05:00 PM ET
    $EOLS
    Biotechnology: Pharmaceutical Preparations
    Health Care